Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo
Cutaneous squamous cell carcinoma (SCC) is the most prevalent cancer worldwide, increasing the cost of healthcare services and with a high rate of morbidity. Its etiology is linked to chronic ultraviolet (UV) exposure that leads to malignant transformation of keratinocytes. Invasive growth and metas...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/7/1993 |
| _version_ | 1797561784307023872 |
|---|---|
| author | Gabriella Pasqual-Melo Thiago Nascimento Larissa Juliani Sanches Fernanda Paschoal Blegniski Julya Karen Bianchi Sanjeev Kumar Sagwal Julia Berner Anke Schmidt Steffen Emmert Klaus-Dieter Weltmann Thomas von Woedtke Rajesh Kumar Gandhirajan Alessandra Lourenço Cecchini Sander Bekeschus |
| author_facet | Gabriella Pasqual-Melo Thiago Nascimento Larissa Juliani Sanches Fernanda Paschoal Blegniski Julya Karen Bianchi Sanjeev Kumar Sagwal Julia Berner Anke Schmidt Steffen Emmert Klaus-Dieter Weltmann Thomas von Woedtke Rajesh Kumar Gandhirajan Alessandra Lourenço Cecchini Sander Bekeschus |
| author_sort | Gabriella Pasqual-Melo |
| collection | DOAJ |
| description | Cutaneous squamous cell carcinoma (SCC) is the most prevalent cancer worldwide, increasing the cost of healthcare services and with a high rate of morbidity. Its etiology is linked to chronic ultraviolet (UV) exposure that leads to malignant transformation of keratinocytes. Invasive growth and metastasis are severe consequences of this process. Therapy-resistant and highly aggressive SCC is frequently fatal, exemplifying the need for novel treatment strategies. Cold physical plasma is a partially ionized gas, expelling therapeutic doses of reactive oxygen and nitrogen species that were investigated for their anticancer capacity against SCC in vitro and SCC-like lesions in vivo. Using the kINPen argon plasma jet, a selective growth-reducing action of plasma treatment was identified in two SCC cell lines in 2D and 3D cultures. In vivo, plasma treatment limited the progression of UVB-induced SSC-like skin lesions and dermal degeneration without compromising lesional or non-lesional skin. In lesional tissue, this was associated with a decrease in cell proliferation and the antioxidant transcription factor Nrf2 following plasma treatment, while catalase expression was increased. Analysis of skin adjacent to the lesions and determination of global antioxidant parameters confirmed the local but not systemic action of the plasma anticancer therapy in vivo. |
| first_indexed | 2024-03-10T18:19:31Z |
| format | Article |
| id | doaj.art-13f499ce038a41fd8b850828cbd8bcfc |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T18:19:31Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-13f499ce038a41fd8b850828cbd8bcfc2023-11-20T07:26:39ZengMDPI AGCancers2072-66942020-07-01127199310.3390/cancers12071993Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In VivoGabriella Pasqual-Melo0Thiago Nascimento1Larissa Juliani Sanches2Fernanda Paschoal Blegniski3Julya Karen Bianchi4Sanjeev Kumar Sagwal5Julia Berner6Anke Schmidt7Steffen Emmert8Klaus-Dieter Weltmann9Thomas von Woedtke10Rajesh Kumar Gandhirajan11Alessandra Lourenço Cecchini12Sander Bekeschus13ZIK <i>plasmatis</i>, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, GermanyDepartment of General Pathology, State University of Londrina, Rodovia Celso Garcia Cid, Londrina 86051-990, BrazilDepartment of General Pathology, State University of Londrina, Rodovia Celso Garcia Cid, Londrina 86051-990, BrazilDepartment of General Pathology, State University of Londrina, Rodovia Celso Garcia Cid, Londrina 86051-990, BrazilDepartment of General Pathology, State University of Londrina, Rodovia Celso Garcia Cid, Londrina 86051-990, BrazilZIK <i>plasmatis</i>, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, GermanyZIK <i>plasmatis</i>, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, GermanyZIK <i>plasmatis</i>, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, GermanyClinic for Dermatology and Venereology, Rostock University Medical Center, Strempelstr. 13, 18057 Rostock, GermanyZIK <i>plasmatis</i>, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, GermanyZIK <i>plasmatis</i>, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, GermanyZIK <i>plasmatis</i>, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, GermanyDepartment of General Pathology, State University of Londrina, Rodovia Celso Garcia Cid, Londrina 86051-990, BrazilZIK <i>plasmatis</i>, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, GermanyCutaneous squamous cell carcinoma (SCC) is the most prevalent cancer worldwide, increasing the cost of healthcare services and with a high rate of morbidity. Its etiology is linked to chronic ultraviolet (UV) exposure that leads to malignant transformation of keratinocytes. Invasive growth and metastasis are severe consequences of this process. Therapy-resistant and highly aggressive SCC is frequently fatal, exemplifying the need for novel treatment strategies. Cold physical plasma is a partially ionized gas, expelling therapeutic doses of reactive oxygen and nitrogen species that were investigated for their anticancer capacity against SCC in vitro and SCC-like lesions in vivo. Using the kINPen argon plasma jet, a selective growth-reducing action of plasma treatment was identified in two SCC cell lines in 2D and 3D cultures. In vivo, plasma treatment limited the progression of UVB-induced SSC-like skin lesions and dermal degeneration without compromising lesional or non-lesional skin. In lesional tissue, this was associated with a decrease in cell proliferation and the antioxidant transcription factor Nrf2 following plasma treatment, while catalase expression was increased. Analysis of skin adjacent to the lesions and determination of global antioxidant parameters confirmed the local but not systemic action of the plasma anticancer therapy in vivo.https://www.mdpi.com/2072-6694/12/7/1993kINPenplasma medicineplasma sourcesreactive oxygen and nitrogen speciescutaneous squamous cell carcinoma (SCC) |
| spellingShingle | Gabriella Pasqual-Melo Thiago Nascimento Larissa Juliani Sanches Fernanda Paschoal Blegniski Julya Karen Bianchi Sanjeev Kumar Sagwal Julia Berner Anke Schmidt Steffen Emmert Klaus-Dieter Weltmann Thomas von Woedtke Rajesh Kumar Gandhirajan Alessandra Lourenço Cecchini Sander Bekeschus Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo Cancers kINPen plasma medicine plasma sources reactive oxygen and nitrogen species cutaneous squamous cell carcinoma (SCC) |
| title | Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo |
| title_full | Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo |
| title_fullStr | Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo |
| title_full_unstemmed | Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo |
| title_short | Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo |
| title_sort | plasma treatment limits cutaneous squamous cell carcinoma development in vitro and in vivo |
| topic | kINPen plasma medicine plasma sources reactive oxygen and nitrogen species cutaneous squamous cell carcinoma (SCC) |
| url | https://www.mdpi.com/2072-6694/12/7/1993 |
| work_keys_str_mv | AT gabriellapasqualmelo plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT thiagonascimento plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT larissajulianisanches plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT fernandapaschoalblegniski plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT julyakarenbianchi plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT sanjeevkumarsagwal plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT juliaberner plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT ankeschmidt plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT steffenemmert plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT klausdieterweltmann plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT thomasvonwoedtke plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT rajeshkumargandhirajan plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT alessandralourencocecchini plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo AT sanderbekeschus plasmatreatmentlimitscutaneoussquamouscellcarcinomadevelopmentinvitroandinvivo |